EGFR and lung carcinoma: During the International Association for the Study of Lung Cancer (IASLC) 2020 World Conference on Lung Cancer, Tsuboi et al. presented the design of NeoADAURA, a phase III, randomized, multicenter study of neoadjuvant osimertinib in EGFR mutant resectable stage II‒IIIB NSCLC.